What To Expect From Hims & Hers Health's (HIMS) Q4 Earnings

Telehealth company Hims & Hers Health (NYSE:HIMS) will be announcing earnings results this Monday after market close. Here’s what to look for.

Hims & Hers Health beat analysts’ revenue expectations last quarter, reporting revenues of $599 million, up 49.2% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS estimates but revenue guidance for next quarter missing analysts’ expectations significantly. It added 32,000 customers to reach a total of 2.47 million.

Is Hims & Hers Health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Hims & Hers Health’s revenue to grow 28.4% year on year, slowing from the 95.1% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hims & Hers Health rarely misses Wall Street’s revenue estimates.

Looking at Hims & Hers Health’s peers in the healthcare technology segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Tandem Diabetes delivered year-on-year revenue growth of 15%, beating analysts’ expectations by 4.9%, and Omnicell reported revenues up 2.3%, in line with consensus estimates. Tandem Diabetes traded up 32.7% following the results while Omnicell was down 20.6%.

Read our full analysis of Tandem Diabetes’s results here and Omnicell’s results here.

Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.2% on average over the last month. Hims & Hers Health is down 46.7% during the same time and is heading into earnings with an average analyst price target of $27.46 (compared to the current share price of $15.78).

P.S. STOP buying the AI stocks everyone's talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.